Moody's downgrades Dow to Baa2 from Baa1; outlook negative

Moody’s Ratings has downgraded The Dow Chemical Company’s senior unsecured credit rating to Baa2 from Baa1, maintaining a negative outlook, citing depressed earnings, significantly weakened credit metrics (Net debt/EBITDA at 5.2x), and governance concerns over elevated shareholder returns despite poor performance. The downgrade reflects a prolonged market downturn characterized by weak global demand, unfavorable costs, and restructuring expenses, with Moody's expecting continued earnings weakness and elevated debt leverage for the next 12-18 months. While Dow benefits from its scale, diversity, and strong liquidity, the negative outlook persists despite management's planned $6 billion in 2025 cash support initiatives.

Analysis

Moody's has downgraded Dow Chemical's senior unsecured credit rating to Baa2 from Baa1, maintaining a negative outlook, signaling escalating financial pressure. The downgrade is rooted in a severe deterioration of credit metrics, evidenced by the adjusted Net debt/EBITDA ratio climbing to 5.2x as of March 2025 from 1.9x at the end of 2022. This financial strain stems from a prolonged cyclical downturn, with Moody's forecasting a further earnings decline in 2025 due to lower selling prices, adverse feedstock costs, and restructuring expenses. The weak demand environment is attributed to high U.S. interest rates impacting construction, a sluggish Chinese property sector, and subdued European industrial activity. Critically, Moody's flagged governance concerns over Dow's strategy of maintaining elevated dividend payouts and share repurchases amid weakening performance. While management has outlined a $6 billion cash support plan for 2025, including asset sales and cost reductions, the negative outlook reflects expectations of a slow recovery, negative free cash flow, and elevated leverage persisting for the next 12 to 18 months, despite the company's strong liquidity and scale.

Key Decisions for Investors

• Investors should re-evaluate the risk associated with Dow's debt, as the Baa2 rating is only two notches above non-investment grade and the negative outlook could signal further downgrades and increased borrowing costs.
• Scrutinize management's capital allocation policy, as the continuation of elevated dividends and buybacks, cited by Moody's as a governance concern, may be unsustainable amid projections of negative free cash flow and could pressure the balance sheet further.
• Closely monitor the execution of management's $6 billion cash support plan for 2025, as the successful completion of asset sales and the outcome of the Nova litigation are now critical catalysts for financial stabilization.
• Consider the stock's sensitivity to macroeconomic headwinds, as any recovery is contingent on improvements in global construction, Chinese property markets, and European industrial activity, making these key indicators to watch for a potential turnaround.